Sun Pharma gets exclusive global licence for CSIR-IICT patents
Sun Pharma gets exclusive global license for CSIR-IICT’s patents related to certain compounds with potential therapeutic activity across multiple indications
Sun Pharmaceutical Industries today announced that it has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in its specialty focus areas.
Under the agreement, Sun Pharma gets exclusive global licencee for the said patents and any other future patents covered in the agreement. The company will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totaling up to Rs 2.40 billion, plus royalties on net sales from commercialisation of the products developed using these patents, Sun Pharmaceutical said in a statement. Sun Pharma will be responsible for development, regulatory filings, manufacturing and commercialisation of these products.
Dilip Shanghvi, managing director, Sun Pharma said, “This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline. CSIR-IICT is known for its high-quality research and we are proud to be associated with them. We are making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally. Our collaboration with CSIR-IICT is a step in this direction.”
A successful clinical development of these potential compounds may enable Sun Pharma to commercialise pharmaceutical products for various therapeutic indications over the long term.